NYSE
AMRX

Amneal Pharmaceuticals Inc Class A

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Amneal Pharmaceuticals Inc Class A Stock Price

Vitals

Today's Low:
$3.82
Today's High:
$4.1
Open Price:
$3.85
52W Low:
$1.665
52W High:
$4.6
Prev. Close:
$3.84
Volume:
953190

Company Statistics

Market Cap.:
$534.37 million
Book Value:
1.97
Revenue TTM:
$2.21 billion
Operating Margin TTM:
9.04%
Gross Profit TTM:
$791.46 million
Profit Margin:
-5.88%
Return on Assets TTM:
3.23%
Return on Equity TTM:
-85.96%

Company Profile

Amneal Pharmaceuticals Inc Class A had its IPO on 2009-01-15 under the ticker symbol AMRX.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Amneal Pharmaceuticals Inc Class A has a staff strength of 0 employees.

Stock update

Shares of Amneal Pharmaceuticals Inc Class A opened at $3.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.82 - $4.1, and closed at $4.

This is a +4.17% increase from the previous day's closing price.

A total volume of 953,190 shares were traded at the close of the day’s session.

In the last one week, shares of Amneal Pharmaceuticals Inc Class A have slipped by -5.21%.

Amneal Pharmaceuticals Inc Class A's Key Ratios

Amneal Pharmaceuticals Inc Class A has a market cap of $534.37 million, indicating a price to book ratio of 1.1865 and a price to sales ratio of 0.3221.

In the last 12-months Amneal Pharmaceuticals Inc Class A’s revenue was $2.21 billion with a gross profit of $791.46 million and an EBITDA of $440.21 million. The EBITDA ratio measures Amneal Pharmaceuticals Inc Class A's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Amneal Pharmaceuticals Inc Class A’s operating margin was 9.04% while its return on assets stood at 3.23% with a return of equity of -85.96%.

In Q4, Amneal Pharmaceuticals Inc Class A’s quarterly earnings growth was a negative -94.9% while revenue growth was a positive 13.6%.

Amneal Pharmaceuticals Inc Class A’s PE and PEG Ratio

Forward PE
6.2972
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.77 per share while it has a forward price to earnings multiple of 6.2972 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amneal Pharmaceuticals Inc Class A’s profitability.

Amneal Pharmaceuticals Inc Class A stock is trading at a EV to sales ratio of 1.4597 and a EV to EBITDA ratio of 24.2437. Its price to sales ratio in the trailing 12-months stood at 0.3221.

Amneal Pharmaceuticals Inc Class A stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.80 billion
Total Liabilities
$752.80 million
Operating Cash Flow
$-11466000.00
Capital Expenditure
$32.72 million
Dividend Payout Ratio
0%

Amneal Pharmaceuticals Inc Class A ended 2024 with $3.80 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.80 billion while shareholder equity stood at $183.98 million.

Amneal Pharmaceuticals Inc Class A ended 2024 with $0 in deferred long-term liabilities, $752.80 million in other current liabilities, 1514000.00 in common stock, $-406183000.00 in retained earnings and $598.85 million in goodwill. Its cash balance stood at $25.98 million and cash and short-term investments were $25.98 million. The company’s total short-term debt was $104,639,000 while long-term debt stood at $2.59 billion.

Amneal Pharmaceuticals Inc Class A’s total current assets stands at $1.41 billion while long-term investments were $0 and short-term investments were $0. Its net receivables were $741.79 million compared to accounts payable of $538.20 million and inventory worth $530.74 million.

In 2024, Amneal Pharmaceuticals Inc Class A's operating cash flow was $-11466000.00 while its capital expenditure stood at $32.72 million.

Comparatively, Amneal Pharmaceuticals Inc Class A paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4
52-Week High
$4.6
52-Week Low
$1.665
Analyst Target Price
$5.33

Amneal Pharmaceuticals Inc Class A stock is currently trading at $4 per share. It touched a 52-week high of $4.6 and a 52-week low of $4.6. Analysts tracking the stock have a 12-month average target price of $5.33.

Its 50-day moving average was $3.6 and 200-day moving average was $2.48 The short ratio stood at 6.23 indicating a short percent outstanding of 0%.

Around 1087.8% of the company’s stock are held by insiders while 6778.6% are held by institutions.

Frequently Asked Questions About Amneal Pharmaceuticals Inc Class A

The stock symbol (also called stock or share ticker) of Amneal Pharmaceuticals Inc Class A is AMRX

The IPO of Amneal Pharmaceuticals Inc Class A took place on 2009-01-15

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$28.7
0.19
+0.67%
$4.21
0.02
+0.48%
CRESTCHEM LTD. (CRSTCHM)
$67.99
1.28
+1.92%
CUPID LTD.-$ (CUPID)
$390.1
-36.35
-8.52%
$0.94
0
+0.41%
$74.46
0.15
+0.2%
$544.1
-19.6
-3.48%
$187.85
-1.2
-0.63%
DCX Systems Ltd (DCXINDIA)
$308.65
-34.5
-10.05%
Arshiya Limited (ARSHIYA)
$5.2
-0.1
-1.89%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson’s disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Address

400 Crossing Boulevard, Bridgewater, NJ, United States, 08807